Presentation of the Hemerion technology, meeting with investors, neurosurgeons and care centers, discussions about North American regulations: Hemerion has set new milestones for its international development during a 5-day mission in Boston.
With more than 13,000 new cases of glioblastoma (GBM) diagnosed each year, the United States is, along with Europe, one of the most affected territories by this aggressive form of brain cancer. Since its creation, Hemerion has been working on its development in this market and has forged very close ties with the clinical teams of the Mount Sinai System in New York, one of the country’s most important neurosurgery centers.
A mission to present Hemerion’s technology to leaders in neurosurgery
The Hemerion team participated in a five-day mission to Boston in April as part of the NETVA (New Technology Venture Accelerator) program, led by the French Embassy’s Science and Technology Department (Ministry of Europe and Foreign Affairs), the French Consulate in Boston and supported by Bpifrance and the French Ministry of Higher Education, Research and Innovation.
NETVA offers a complete program of personalized support, opportunity analysis and development of technological partnerships in the United States.
As part of this program, Hemerion was able to present its glioblastoma treatment technology to numerous clinical leaders in neurosurgery (Tufts Medical Center, Mass General Hospital, Boston Children’s Hospital, Brigham and Women’s Hospital, etc.).
These meetings provided an opportunity to detail how Hemerion technology can be integrated into the American standard of care, to demonstrate the improvements made to current treatments and to gather feedback from practitioners.
A mission to prepare the implementation of future clinical studies
Maximilien Vermandel, CEO, and Clément Dupont, CTO, also met with numerous investors and executives from French companies based in the US, including Nanobiotix and Sanofi. Their objective was to better understand the specificities of the American market and to prepare the next financial round.
This mission to Boston also allowed to examine the regulatory procedures initiated with the Food and Drugs Administration (FDA) with the help of the Voisin Consulting Life Sciences’ team.
